Precision Biosciences Inc (DTIL) Stock Analysis and Metrics

Precision Biosciences

NASDAQ: DTIL

$7.62 ▲ +0.33 (+4.53%)

At close: Jul 27, 2026 · 9:42 AM UTC

Financial Ratios

Market Cap181.80 Mn

P/E-3.95

P/S4.03

Div. Yield0.00

Total Debt (Qtr)22.42 Mn

Revenue Growth (1y) (Qtr)37,272.41

Add ratio to table…

About

Precision Biosciences Inc is a clinical stage gene editing company that develops in vivo therapeutic candidates using its proprietary ARCUS nuclease platform. The company focuses on creating permanent genetic treatments for serious unmet medical needs, including infectious diseases such as hepatitis B and genetic disorders like Duchenne muscular dystrophy. Its ARCUS technology enables precise DNA editing through a compact, single‑component enzyme that does not require guide RNA.

Precision Biosciences generates revenue primarily through licensing and collaboration agreements with biopharma partners. These arrangements provide upfront payments, milestone payments upon achievement of development or regulatory goals, and royalties on net sales of any resulting products. The company also receives payments from its exclusive license with Duke University and may earn income from future product sales once its therapies reach commercialization.

Within the gene editing sector, Precision Biosciences competes with established players such as CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Beam Therapeutics, Prime Medicine, Tune Therapeutics and Verve Therapeutics. Its competitive edge lies in the ARCUS platform’s unique staggered cut, small molecular size that fits within AAV vectors, and the absence of a required guide RNA, which together aim to improve delivery efficiency and editing precision. These characteristics are intended to differentiate its product candidates and support a stronger safety and efficacy profile versus existing technologies.

The company’s therapeutic programs target patients with chronic hepatitis B, Duchenne muscular dystrophy, mitochondrial disease, and rare genetic disorders such as ornithine transcarbamylase deficiency. In addition, Precision Biosciences collaborates with partners including Caribou Biosciences, TG Therapeutics, Imugene, Novartis and iECURE, who develop or commercialize products based on its ARCUS technology. These collaborations extend the company’s reach to broader patient populations and therapeutic areas.

Investment Thesis

▲ Bull case

Precision BioSciences' PBGENE-HBV program has demonstrated transformative clinical evidence that directly addresses the core pathology of chronic hepatitis B, with first-ever proof of cccDNA elimination and inactivation in human liver biopsies, a breakthrough unmatched by any existing or developmental therapy. The ELIMINATE-B trial showed a 1-log reduction in cccDNA transcripts after just two doses at 0.4 mg/kg, with cumulative editing reaching 80% of remaining cccDNA after three administrations, indicating a clear path to durable viral cure. This mechanism aligns precisely with FDA guidance that eradication of HBV DNA is the optimal approval endpoint, positioning PBGENE-HBV as a potential first-in-class curative therapy rather than a lifelong suppression treatment, which could redefine the standard of care and unlock significant premium valuation if approved.
The company's financial position is substantially stronger than recent losses suggest, with $125.8 million in cash as of Q1 FY26 and an expected runway through 2028, supported by non-dilutive milestone payments from partnered programs like the $7.5 million from TG Therapeutics for azer-cel progress in multiple sclerosis and the $8 million from Imugene in 2025. These partnerships validate the ARCUS platform's versatility across therapeutic areas and provide critical funding without equity dilution, reducing near-term financing risk and allowing management to focus exclusively on clinical milestones for PBGENE-HBV and PBGENE-DMD, which are expected to deliver multiple value-inflection points in 2026 including initial FUNCTION-DMD data and further ELIMINATE-B biomarker readouts.
PBGENE-DMD is poised to capture a large unmet need in Duchenne muscular dystrophy by targeting approximately 60% of patients with exon 45-55 mutations, a segment ignored by current microdystrophin therapies that offer minimal functional benefit. Recent preclinical data from ASGCT 2026 demonstrated superior efficacy in early-juvenile mice, supporting intervention in younger patients (2-3 years old) — a key demographic in the ongoing FUNCTION-DMD trial — where gene editing avoids the AAV dilution problem that plagues transgene-based approaches as muscles grow. With IND clearance, Fast Track designation, Orphan Drug status, and eligibility for a Priority Review Voucher, PBGENE-DMD has a de-risked regulatory path and the potential for accelerated approval, with initial clinical data expected by year-end 2026 that could catalyze a significant re-rating of the stock as the platform's broader applicability beyond hepatitis B becomes evident.

Precision BioSciences' PBGENE-HBV program has demonstrated transformative clinical evidence that directly addresses the core pathology of chronic hepatitis B, with first-ever proof of cccDNA elimination and inactivation in human liver biopsies, a breakthrough unmatched by any existing or developmental therapy. The ELIMINATE-B trial showed a 1-log reduction in cccDNA transcripts after just two doses at 0.4 mg/kg, with cumulative editing reaching 80% of remaining cccDNA after three administrations, indicating a clear path to durable viral cure. This mechanism aligns precisely with FDA guidance that eradication of HBV DNA is the optimal approval endpoint, positioning PBGENE-HBV as a potential first-in-class curative therapy rather than a lifelong suppression treatment, which could redefine the standard of care and unlock significant premium valuation if approved.
The company's financial position is substantially stronger than recent losses suggest, with $125.8 million in cash as of Q1 FY26 and an expected runway through 2028, supported by non-dilutive milestone payments from partnered programs like the $7.5 million from TG Therapeutics for azer-cel progress in multiple sclerosis and the $8 million from Imugene in 2025. These partnerships validate the ARCUS platform's versatility across therapeutic areas and provide critical funding without equity dilution, reducing near-term financing risk and allowing management to focus exclusively on clinical milestones for PBGENE-HBV and PBGENE-DMD, which are expected to deliver multiple value-inflection points in 2026 including initial FUNCTION-DMD data and further ELIMINATE-B biomarker readouts.
PBGENE-DMD is poised to capture a large unmet need in Duchenne muscular dystrophy by targeting approximately 60% of patients with exon 45-55 mutations, a segment ignored by current microdystrophin therapies that offer minimal functional benefit. Recent preclinical data from ASGCT 2026 demonstrated superior efficacy in early-juvenile mice, supporting intervention in younger patients (2-3 years old) — a key demographic in the ongoing FUNCTION-DMD trial — where gene editing avoids the AAV dilution problem that plagues transgene-based approaches as muscles grow. With IND clearance, Fast Track designation, Orphan Drug status, and eligibility for a Priority Review Voucher, PBGENE-DMD has a de-risked regulatory path and the potential for accelerated approval, with initial clinical data expected by year-end 2026 that could catalyze a significant re-rating of the stock as the platform's broader applicability beyond hepatitis B becomes evident.

▼ Bear case

Despite promising biopsy data, the ELIMINATE-B trial remains in early Phase 1 with only 16 patients treated and 38 doses administered as of May 2026, and no clinical evidence yet of sustained HBsAg loss off nucleos(t)ide analogs or durable HBV DNA undetectability — the actual endpoints required for regulatory approval. The company has not disclosed any data showing cccDNA elimination translates to functional cure after treatment cessation, a critical gap since current standard of care already achieves HBsAg decline in most patients during therapy; the true test will be whether PBGENE-HBV enables finite treatment duration, which remains unproven and introduces significant binary risk if relapse occurs post-therapy, potentially undermining the curative narrative.
The ARCUS platform faces inherent scalability and safety challenges that could impede commercialization, particularly with lipid nanoparticle (LNP) delivery in PBGENE-HBV, which caused dose-limiting hypotension events requiring protocol modifications like slower infusion rates and increased steroids — interventions that may not be feasible in real-world settings and could limit dosing flexibility or increase complexity. Furthermore, the company's dependence on a single proprietary technology creates vulnerability if competing gene-editing platforms (e.g., CRISPR-based systems with improved delivery or specificity) demonstrate superior profiles, a risk highlighted in its own disclosures about potential advantages held by other technologies, which could erode Precision's moat despite early clinical progress.
Precision's revenue model remains heavily reliant on volatile milestone payments from partners rather than recurring product sales, as evidenced by Q1 FY26 revenue of $10.8 million being driven almost entirely by the TG Therapeutics azer-cel milestone and a legacy agriculture deal, with no near-term prospect of commercial revenue from its wholly-owned pipeline before 2029 at the earliest. This dependence makes financial performance unpredictable and susceptible to delays in partner programs, while the company continues to burn significant cash — $18.4 million net loss in Q1 FY26 — raising concerns about whether the projected 2028 cash runway is achievable if clinical trials encounter setbacks or if additional funding becomes necessary on unfavorable terms, potentially diluting shareholders before any therapeutic success is validated.

Despite promising biopsy data, the ELIMINATE-B trial remains in early Phase 1 with only 16 patients treated and 38 doses administered as of May 2026, and no clinical evidence yet of sustained HBsAg loss off nucleos(t)ide analogs or durable HBV DNA undetectability — the actual endpoints required for regulatory approval. The company has not disclosed any data showing cccDNA elimination translates to functional cure after treatment cessation, a critical gap since current standard of care already achieves HBsAg decline in most patients during therapy; the true test will be whether PBGENE-HBV enables finite treatment duration, which remains unproven and introduces significant binary risk if relapse occurs post-therapy, potentially undermining the curative narrative.
The ARCUS platform faces inherent scalability and safety challenges that could impede commercialization, particularly with lipid nanoparticle (LNP) delivery in PBGENE-HBV, which caused dose-limiting hypotension events requiring protocol modifications like slower infusion rates and increased steroids — interventions that may not be feasible in real-world settings and could limit dosing flexibility or increase complexity. Furthermore, the company's dependence on a single proprietary technology creates vulnerability if competing gene-editing platforms (e.g., CRISPR-based systems with improved delivery or specificity) demonstrate superior profiles, a risk highlighted in its own disclosures about potential advantages held by other technologies, which could erode Precision's moat despite early clinical progress.
Precision's revenue model remains heavily reliant on volatile milestone payments from partners rather than recurring product sales, as evidenced by Q1 FY26 revenue of $10.8 million being driven almost entirely by the TG Therapeutics azer-cel milestone and a legacy agriculture deal, with no near-term prospect of commercial revenue from its wholly-owned pipeline before 2029 at the earliest. This dependence makes financial performance unpredictable and susceptible to delays in partner programs, while the company continues to burn significant cash — $18.4 million net loss in Q1 FY26 — raising concerns about whether the projected 2028 cash runway is achievable if clinical trials encounter setbacks or if additional funding becomes necessary on unfavorable terms, potentially diluting shareholders before any therapeutic success is validated.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	68,334.77 Bn	-31.89 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,887.92 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,132.35 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	475.16 Bn	0.00 Bn	82.79	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	122.97 Bn	0.00 Bn	10.07	-
6	REGN	Regeneron Pharmaceuticals, Inc.	69.33 Bn	0.00 Bn	4.65	1.99 Bn
7	BLTE	Belite Bio, Inc	62.61 Bn	368.28 Bn	-	-
8	ARGX	Argenx Se	57.10 Bn	0.00 Bn	10.84	-

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password